目的 观察小剂量阿帕替尼加原靶向药物治疗对第一代表皮生长因子酪氨酸激酶抑制剂(EGFR-TKIs)继发性耐药的晚期非小细胞肺癌(NSCLC)的有效性和安全性.方法 对2016年3月-2016年11月期间,11例接受厄洛替尼、吉非替尼和埃克替尼治疗后出现影像学进展的晚期NSCLC患者,在继续按原剂量服用原靶向药物的基础上加用阿帕替尼250 mg口服,每日1次,每4周进行CT复查,并观察相关毒副反应.结果 11例患者中2例在12周内进展,1例自行停药,8例病情稳定并继续接受治疗,中位疾病进展时间(TTP)为12周.1例出现3+蛋白尿,2例皮疹,2例Ⅱ级乏力,2例食欲减退.结论 对第一代EGFR-TKIs耐药的晚期NSCLC患者采用小剂量阿帕替尼加原靶向药物治疗,部分患者可以显示良好的疗效,并且毒副反应轻微.%Objective To investigate the efficacy and safety of low dose apatinib plus original targeted drug for patients with advanced non-small cell lung cancer (NSCLC) and acquired resistance to first-generation epithelial growth factor receptor - tyrosine kinase inhibi-tors (EGFR-TKIs). Methods Between March 2016 and November 2016, 11 advanced NSCLC patients with acquired resistance to erlotinib, gefitinib or icotinib were treated with original targeted drug plus oral administration of apatinib, 250 mg, once daily. Patients had CT scan every 4 weeks. Observe the related toxic and side effects in the meanwhile. Results Of the 11 patients, two cases had disease progress within 12 weeks, one case had drug withdrawal by himself. Eight cases had disease controlled and remain in treatment. The median time to progress (TTP) was 12 weeks. One case had proteinuria 3+, and two cases appeared rash, and two cases felt fatigue, and two cases lost their appetite. Conclusion The low dose apatinib plus original targeted drug had good efficacy and tolerated side effects on advanced NSCLC patients with acquired resistance to first-generation EGFR-TKIs.
展开▼
